Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (75.0%)
N/A1 (25.0%)

Trials by Status

terminated125%
withdrawn125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_2

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

NCT01343641
completednot_applicable

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

NCT00395291
terminatedphase_2

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

NCT00128115
completedphase_2

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

NCT00074529

Clinical Trials (4)

Showing 4 of 4 trials
NCT01343641Phase 2

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Withdrawn
NCT00395291Not Applicable

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

Completed
NCT00128115Phase 2

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Terminated
NCT00074529Phase 2

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4